SCHEMBL17560962

SCHEMBL17560962

C/C(=N\N=C(N)N)c1ccc(C(C)(C)C)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FURIN P09958 6/20 0.73
LMNA P02545 1/20 0.61
POLB P06746 1/20 0.61
GRIN2D O15399 2/20 0.51
GRIN3B O60391 2/20 0.51
GRIN1 Q05586 2/20 0.51
GRIN2A Q12879 2/20 0.51
GRIN2B Q13224 2/20 0.51
GRIN2C Q14957 2/20 0.51
GRIN3A Q8TCU5 2/20 0.51
NPFFR2 Q9Y5X5 2/20 0.51
MAPT P10636 1/20 0.50
ALOX12 P18054 1/20 0.50
SLC22A2 O15244 1/20 0.50
SLC22A1 O15245 1/20 0.50
SLC22A3 O75751 1/20 0.50
KCNH2 Q12809 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17560965 1.00 FURIN (0.73) FURINLMNAPOLBGRIN2DGRIN3B
SCHEMBL17560964 1.00 FURIN (0.73) FURINLMNAPOLBGRIN2DGRIN3B
2-(1-Phenylethylidene)Hydrazinecarboximidamide SCHEMBL12217973 0.75 FURIN (0.78) FURINLMNAPOLBNPFFR2KCNH2
SCHEMBL4833231 0.75 CA9 (0.55) LMNAPOLBMAPTALOX12SLC22A2
SCHEMBL4833241 0.75 CA9 (0.55) LMNAPOLBMAPTALOX12SLC22A2
Hydrochloric Acid SCHEMBL1886710 0.73 FURIN (0.73) FURINLMNAPOLBNPFFR2KCNH2
SCHEMBL13445118 0.72 FURIN (0.70) FURINLMNAPOLBGRIN2DGRIN3B
SCHEMBL31255151 0.72 ESRRG (0.68) LMNAPOLBMAPTALOX12MEN1
SCHEMBL16437274 0.71 MAPT (0.47) LMNAPOLBMAPTALOX12SLC22A2
SCHEMBL14339587 0.69 TNF (0.51) LMNAPOLBGRIN2DGRIN3BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2017-10-12 US claimed
EP-3188722-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS Neoculi Pty Ltd (AU) 2017-07-12 EP claimed
WO-2016033635-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2016-03-10 WO claimed
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2017-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS DPM1, ABCB11, PIGS FURIN 362/4885LMNA 2337/4885POLB 3872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.